Eton Pharmaceuticals, Inc (ETON) Tuesday said that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for ET-600, a proprietary desmopressin oral solution.
The Prescription Drug User Fee Act (PDUFA) target action date is February 25, 2026.
ET-600 is a proprietary formulation of desmopressin oral solution developed for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency (AVP-D).
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.